Epidemiology and Aetiology of Non-melanoma Skin Cancer

  • Zubair Hasan
  • Faruque Riffat
Part of the Head and Neck Cancer Clinics book series (HNCC)


Skin cancer can be categorized broadly into cutaneous melanoma and nonmelanoma skin cancer (NMSC). Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the most common types of NMSC. Apart from these, rarer cutaneous malignancies, such as Merkel cell carcinoma (MCC) and malignancies of the adnexal structures, also occur. NMSC is by far the most common malignancy encountered in the human body, and is found frequently in primary care settings, which makes it an important public health consideration. It is managed by a variety of medical practitioners, being of multidisciplinary interest to otolaryngologists, head and neck surgeons, plastic surgeons, dermatologists, radiation oncologists, and primary care physicians.


Squamous Cell Carcinoma Basal Cell Carcinoma Merkel Cell Carcinoma Heart Transplant Recipient Nonmelanoma Skin Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kricker A, Armstrong BK, English DR. Sun exposure and non-melanocytic skin cancer. Cancer Causes Control. 1994;5:367–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Staples MP, Elwood M, Burton RC, et al. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust. 2006;184:6–10.PubMedGoogle Scholar
  3. 3.
    Melissa Goodwin, Australian Institute of Health and Welfare, Cancer Australia. Non-melanoma skin cancer: general practice consultations, hospitalisation and mortality. Canberra: Australian Institute of Health and Welfare; 2008.Google Scholar
  4. 4.
    Fransen M, Karahalios A, Sharma N, et al. Non-melanoma skin cancer in Australia. Med J Aust. 2012;197:565–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Montague M, Borland R, Sinclair C. Slip! Slop! Slap! and SunSmart, 1980–2000: skin cancer control and 20 years of population-based campaigning. Health Educ Behav. 2001;28:290–305.CrossRefPubMedGoogle Scholar
  6. 6.
    Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer in Australia: an overview 2012. Canberra: Australian Institute of Health and Welfare and Australasian Association of Cancer Registries; 2012.Google Scholar
  7. 7.
    Jensen AØ, Lamberg AL, Jacobsen JB, et al. Non-melanoma skin cancer and ten-year all-cause mortality: a population-based cohort study. Acta Derm Venereol. 2010;90:362–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Laishram RS, Banerjee A, Punyabati P, et al. Pattern of skin malignancies in Manipur, India: a 5-year histopathological review. J Pak Assoc Dermatol. 2012;20:4.Google Scholar
  9. 9.
    Deo SV, Hazarika S, Shukla NK, et al. Surgical management of skin cancers: experience from a regional cancer centre in North India. Indian J Cancer. 2005;42:145–50.CrossRefPubMedGoogle Scholar
  10. 10.
    Panda S. Non-melanoma skin cancer in India: current scenario. Indian J Dermatol. 2010;55:373–8.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Mora RG, Perniciaro C. Cancer of the skin in blacks. I. A review of 163 black patients with cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1981;5:535–43.CrossRefPubMedGoogle Scholar
  12. 12.
    Trakatelli M, Ulrich C, del Marmol V, et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol. 2007;156 Suppl 3:1–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Rhee JS, Matthews BA, Neuburg M, et al. Creation of a quality of life instrument for non-melanoma skin cancer patients. Laryngoscope. 2005;115:1178–85.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics. 2011;29:863–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Donaldson MR, Coldiron BM. No end in sight: the skin cancer epidemic continues. Semin Cutan Med Surg. 2011;30:3–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146:283–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Hoey SE, Devereux CE, Murray L, et al. Skin cancer trends in Northern Ireland and consequences for provision of dermatology services. Br J Dermatol. 2007;156:1301–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Australian Institute of Health and Welfare (AIHW). Health system expenditures on cancer and other neoplasms in Australia 2000–01. Canberra: AIHW; 2005.Google Scholar
  20. 20.
    Yamaguchi Y, Beer JZ, Hearing VJ. Melanin mediated apoptosis of epidermal cells damaged by ultraviolet radiation: factors influencing the incidence of skin cancer. Arch Dermatol Res. 2008;300 Suppl 1:S43–50.CrossRefPubMedGoogle Scholar
  21. 21.
    de Gruijl FR, van Kranen HJ, Mullenders LH. UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B. 2001;63:19–27.CrossRefPubMedGoogle Scholar
  22. 22.
    Glover MT, Deeks JJ, Raftery MJ, et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet. 1997;349:398.CrossRefPubMedGoogle Scholar
  23. 23.
    Rollison DE, Iannacone MR, Messina JL, et al. Case–control study of smoking and non-melanoma skin cancer. Cancer Causes Control. 2012;23:245–54.Google Scholar
  24. 24.
    Yu HS, Liao WT, Chai CY. Arsenic carcinogenesis in the skin. J Biomed Sci. 2006;13:657–66.CrossRefPubMedGoogle Scholar
  25. 25.
    Ouyang YH. Skin cancer of the head and neck. Semin Plast Surg. 2010;24:117–26.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Ramsay HM, Reece SM, Fryer AA, et al. Seven-year prospective study of nonmelanoma skin cancer incidence in UK renal transplant recipients. Transplantation. 2007;84:437–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–74.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Stoff B, Salisbury C, Parker D, et al. Dermatopathology of skin cancer in solid organ transplant recipients. Transplant Rev (Orlando). 2010;24:172–89.CrossRefGoogle Scholar
  29. 29.
    Ong CS, Keogh AM, Kossard S, et al. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol. 1999;40:27–34.CrossRefPubMedGoogle Scholar
  30. 30.
    Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation. 2000;102(19 Suppl 3):III222–7.PubMedGoogle Scholar
  31. 31.
    Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47:1–17; quiz 18–20.CrossRefPubMedGoogle Scholar
  32. 32.
    Sheil AG, Disney AP, Mathew TH, et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc. 1993;25:1383–4.PubMedGoogle Scholar
  33. 33.
    Kanjilal S, Strom SS, Clayman GL, et al. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res. 1995;55:3604–9.PubMedGoogle Scholar
  34. 34.
    Iwasaki JK, Srivastava D, Moy RL, et al. The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol. 2012;66:e167–78.CrossRefPubMedGoogle Scholar
  35. 35.
    Molho-Pessach V, Lotem M. Viral carcinogenesis in skin cancer. Curr Probl Dermatol. 2007;35:39–51.CrossRefPubMedGoogle Scholar
  36. 36.
    Kaae J, Hansen AV, Biggar RJ, et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst. 2010;102:793–801.CrossRefPubMedGoogle Scholar
  37. 37.
    Agelli M, Clegg LX. Epidemiology of primary merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49:832–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Girschik J, Thorn K, Beer TW, et al. Merkel cell carcinoma in Western Australia: a population-based study of incidence and survival. Br J Dermatol. 2011;165:1051–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Güerrissi JO, Quiroga JP. Adnexal carcinomas of the head and neck. Indian J Plast Surg. 2008;41:229–34.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms. Cancer. 2008;113:3372–81.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Nelson BR, Hamlet KR, Gillard M, et al. Sebaceous carcinoma. J Am Acad Dermatol. 1995;33:1–15; quiz 16–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115:158–65.CrossRefPubMedGoogle Scholar
  43. 43.
    Gloster Jr HM. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:355–74; quiz 375–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol. 2007;56:968–73.CrossRefPubMedGoogle Scholar
  45. 45.
    McArthur G. Dermatofibrosarcoma protuberans: recent clinical progress. Ann Surg Oncol. 2007;14:2876–86.CrossRefPubMedGoogle Scholar
  46. 46.
    Dimitropoulos VA. Dermatofibrosarcoma protuberans. Dermatol Ther. 2008;21:428–32.CrossRefPubMedGoogle Scholar
  47. 47.
    Stacchiotti S, Pedeutour F, Negri T, et al. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer. 2011;129:1761–72.CrossRefPubMedGoogle Scholar
  48. 48.
    McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol. 2005;23:866–73.CrossRefPubMedGoogle Scholar
  49. 49.
    Mark RJ, Tran LM, Sercarz J, et al. Angiosarcoma of the head and neck. The UCLA experience 1955 through 1990. Arch Otolaryngol Head Neck Surg. 1993;119:973–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Aust MR, Olsen KD, Lewis JE, et al. Angiosarcomas of the head and neck: clinical and pathologic characteristics. Ann Otol Rhinol Laryngol. 1997;106:943–51.CrossRefPubMedGoogle Scholar
  51. 51.
    Lydiatt WM, Shaha AR, Shah JP. Angiosarcoma of the head and neck. Am J Surg. 1994;168:451–4.CrossRefPubMedGoogle Scholar
  52. 52.
    McIntosh BC, Narayan D. Head and neck angiosarcomas. J Craniofac Surg. 2005;16:699–703.CrossRefPubMedGoogle Scholar
  53. 53.
    Williamson IG, Ramsden RT. Angiosarcoma of maxillary antrum—association with vinyl chloride exposure. J Laryngol Otol. 1988;102:464–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Chen KT, Hoffman KD, Hendricks EJ. Angiosarcoma following therapeutic irradiation. Cancer. 1979;44:2044–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Narula AA, Vallis MP, el-Silimy OE, et al. Radiation induced angiosarcomas of the nasopharynx. Eur J Surg Oncol. 1986;12:147–52.PubMedGoogle Scholar

Copyright information

© Faruque Riffat, Carsten E. Palme, Michael Veness, Rehan Kazi, Raghav C. Dwivedi 2015

Authors and Affiliations

  1. 1.Otolaryngology-Head and Neck Surgery, Westmead HospitalUniversity of New South WalesSydneyAustralia
  2. 2.Otolaryngology-Head and Neck Surgery, Westmead HospitalUniversity of SydneySydneyAustralia

Personalised recommendations